Boothbay Fund Management LLC acquired a new position in shares of Alpha Cognition, Inc. (NASDAQ:ACOG - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 218,015 shares of the company's stock, valued at approximately $1,284,000. Boothbay Fund Management LLC owned approximately 1.36% of Alpha Cognition as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also recently added to or reduced their stakes in the company. Rosalind Advisors Inc. purchased a new stake in shares of Alpha Cognition in the 4th quarter valued at approximately $1,489,000. Aristides Capital LLC purchased a new stake in shares of Alpha Cognition during the 4th quarter worth $1,178,000. Altium Capital Management LLC acquired a new position in shares of Alpha Cognition during the fourth quarter worth $1,620,000. National Bank of Canada FI purchased a new position in Alpha Cognition in the fourth quarter valued at $69,000. Finally, MYDA Advisors LLC acquired a new stake in Alpha Cognition in the fourth quarter valued at $589,000.
Alpha Cognition Trading Up 6.9 %
NASDAQ ACOG traded up $0.41 during trading hours on Friday, hitting $6.39. The company had a trading volume of 105,259 shares, compared to its average volume of 79,280. The firm has a 50 day moving average of $5.12. The stock has a market cap of $102.37 million, a P/E ratio of -2.50 and a beta of 2.50. Alpha Cognition, Inc. has a 1-year low of $3.75 and a 1-year high of $7.00.
Alpha Cognition (NASDAQ:ACOG - Get Free Report) last announced its earnings results on Monday, March 31st. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.03).
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on ACOG. Raymond James upgraded Alpha Cognition to a "moderate buy" rating in a report on Tuesday, March 25th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Alpha Cognition in a research note on Monday, March 31st.
Check Out Our Latest Analysis on Alpha Cognition
About Alpha Cognition
(
Free Report)
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Recommended Stories
Before you consider Alpha Cognition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Cognition wasn't on the list.
While Alpha Cognition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
